TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05797467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy regimens
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX chemotherapy regimens
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
Study: NCT06193915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided hematoma block.
Description: Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind hematoma block
Description: Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
Study: NCT04885218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209 ;placebo
Description: SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
Study: NCT04941833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desogestrel Oral Tablet
Description: Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel Oral Tablet
Description: Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
Study: NCT05530499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond supplementation
Description: Daily consumption of 57g of whole almonds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cookie supplementation
Description: Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
Study: NCT06246669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
Study: NCT05403944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation (SOC)
Description: 6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)
Description: 6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
Study: NCT05346887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Therapy
Description: The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
Study: NCT05156671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab (HAM 8101)
Description: Drip infusion over 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drip infusion over 60 minutes
Study: NCT05515341

Intervention type: DEVICE
Intervention: Commercially Approved Interventional Medical Device/Therapy for Chronic Pain
Description: Commercially Approved Interventional Medical Device/Therapy
Study: NCT05813925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Semaglutide
Description: Participants will receive placebo matched to semaglutide
Study: NCT04985916

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical liniment without investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: ET-01 topical liniment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: ET-01 topical liniment
Study: NCT04963517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 8 weeks personalized, multi-modal exercise with focus on lower extremity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: * Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations.
Study: NCT06540794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP TITRATION
Description: Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
Study: NCT04693013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Anxiety Reduction
Description: Virtual Reality for Anxiety Reduction during suturing of perineum
Study: NCT05817513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release.
Description: Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises for scoliosis treatment.
Description: The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises for scoliosis treatment.
Description: The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises.
Study: NCT06217627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secretome
Description: The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secretome
Description: The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
Study: NCT05158504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation
Description: Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
Study: NCT05609838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water foot bath
Description: A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
Study: NCT06409182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopill
Description: HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
Study: NCT04577599

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Low-dose Computed Tomography (LDCT) Screening
Description: Low Dose CT Scan of the Chest
Study: NCT06509438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
Description: 2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
Study: NCT05144269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercises
Description: Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
Study: NCT06175845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraductal biliary radiofrequency ablation
Description: Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
Study: NCT06220929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Description: The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
Study: NCT06080152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobility Tool
Description: An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
Study: NCT06289218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interferential current
Description: IFC plus exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: KT plus exercise

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: exercise only
Study: NCT06220929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: Ceftriaxone sodium all intravenous formulations

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The saline used in the control group was the same as the saline used in the experimental group to dispense the drug

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo and Mecobalamin tablets look and smell the same.
Study: NCT06519578

Intervention type: DRUG
Group type: OTHER
Intervention: hepatic artery infusion chemotherapy
Description: HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.

Intervention type: DRUG
Group type: OTHER
Intervention: hepatic artery infusion chemotherapy
Description: HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.
Study: NCT05425290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session emotion regulation training
Description: The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
Study: NCT03977922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet group
Description: The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
Study: NCT05477849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Description: 1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5
Study: NCT06031948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active iTBS
Description: Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active iTBS
Description: Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
Study: NCT05174208

Intervention type: OTHER
Intervention: CTE examination
Description: each patients should have undergone CTE examination
Study: NCT06091826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL-101
Description: Subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections
Study: NCT05642091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound Elastography
Description: application of shear wave force by ultrasound elastography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound Elastography
Description: application of shear wave force by ultrasound elastography
Study: NCT05227534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OverC multi-cancer detection blood test
Description: Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
Study: NCT05273515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality and 3D Reconstruction
Description: Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
Study: NCT06248866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
Study: NCT04871451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Study: NCT04826042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization
Study: NCT06177938

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose solution/Glucose solution
Description: Single ingestion of a lactose/glucose solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose solution/Glucose solution
Description: Single ingestion of a lactose/glucose solution.
Study: NCT04896229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talk STEM Familia Treatment Condition
Description: This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
Study: NCT05664425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement
Description: Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)
Study: NCT06407843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Method
Description: In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Physical Therapy
Description: Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Physical Therapy
Description: Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.